Geretti E, Leonard SC, Dumont N, et al. Cyclophosphamide-mediated tumor priming for enhanced delivery and antitumor activity of HER2-targeted liposomal doxorubicin (MM-302). Mol Cancer Ther. 2015;14:2060-2071.
Dumont N, Liu B, DeFilippis RA, et al. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia 2013;15:249-262.
DeFilippis RA, Chang H, Dumont N, et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2012;2:826-839.
Nancy Dumont, Ph.D.
Nancy Dumont is a senior research scientist in the Cancer Program of the Broad Institute of MIT and Harvard, where she works closely with Francisca Vazquez on the Cancer Dependency Map initiative. Dumont joined the Cancer Dependency Map Team to lead the in vivo validation efforts for the top prioritized targets emerging from drug repurposing screens as well as functional genomic screens, the aims of which are to identify novel cancer dependencies that are amenable to therapeutic targeting.
As the in vivo target discovery and advancement lead, Dumont is responsible for identifying and developing appropriate animal models, including cell line and patient-derived xenografts as well as genetically engineered mouse models, to evaluate the activity of genetic and drug repurposing candidates in vivo, and guide decision-making regarding which top priority targets to move forward for therapeutic development. Dumont’s ultimate goal is to help transform current treatment options into life-saving therapies that do not compromise quality of life.
Prior to joining the Broad Institute in March 2017, Dumont worked for four years at Merrimack Pharmaceuticals in Cambridge, MA, where she was responsible for designing and executing preclinical studies to inform clinical decision-making for an antibody-targeted nanoliposome that was being evaluated in a clinical trial for the treatment of metastatic breast cancer. She had previously served as an assistant researcher in the Department of Pathology at the University of California, San Francisco, after completing her postdoctoral fellowship there. During her time at UCSF, she developed in vitro and in vivo assays to examine how the fibroblast and matrix components of the breast microenvironment contribute to early dissemination, tumorigenesis, and metastasis, and published data that challenge the prevailing view that dissemination and metastasis are late events in tumor progression.
Dumont obtained a Ph.D. in cancer biology at Vanderbilt University. She also holds a B.S. and M.S. in physiology from McGill University in Montreal.
Contact Nancy Dumont via email at email@example.com.